Sandbox MEN 2 epi

Revision as of 15:02, 22 September 2015 by Ammu Susheela (talk | contribs)
Jump to navigation Jump to search

__NOTOC_

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Sandbox MEN 2 epi On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox MEN 2 epi

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox MEN 2 epi

CDC on Sandbox MEN 2 epi

Sandbox MEN 2 epi in the news

Blogs on Sandbox MEN 2 epi

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Sandbox MEN 2 epi

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Prevalence

    • Worldwide, the prevalence of multiple endocrine neoplasia type 2 is 2.5 per 100,000 persons in 2010.
    • In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person.
    • MEN2 has been reported in approximately 500 to 1000 families worldwide.[1]
    • 70-80% of all multiple endocrine neoplasia type 2 cases are MEN type 2A.

Incidence

    • In developed countries, the incidence of (insert disease state here) is _____ per 100,000 persons.

Age

  • It can be found in all ages.
  • MEN 2B manifest in early infancy while MEN 2A and familial medullary thyroid carcinoma is found in adulthood.

Gender

  • The prevalence and incidence of multiple endocrine neoplasia type 2 does not vary by gender.

Race

  • The prevalence of multiple endocrine neoplasia type 2 does not vary by race.

Developed Countries

  • In United States the prevalence of multiple endocrine neoplasia type 2 is 1 in 30,000 to 50,000 person..

References